jueves, 11 de marzo de 2021

FDA approves tivozanib for relapsed or refractory advanced renal cell carcinoma | FDA

FDA approves tivozanib for relapsed or refractory advanced renal cell carcinoma | FDA

No hay comentarios:

Publicar un comentario